This week in London, Medicines for Europe gathers regulators and industry leaders to discuss the future of regulation of generic, biosimilar and value added medicines industries.
Our industries, which supply 67% of Europe’s medicines, face an unprecedented set of regulatory challenges in the year ahead. With less than two months to adapt to the UK withdrawal from the European Union, we renew our calls for a clear contingency plan. Pragmatic solutions are needed to avoid medicine supply disruptions as companies finalise the process of separating UK and EU activities. New regulatory requirements including the Falsified Medicines Directive and extended requirements for environmental risk assessment need to be implemented thoughtfully in partnership between industry and regulatory authorities. This will help avoid disproportionate impacts on essential medicines that the majority of European patients rely on.
The EU must seize the opportunity to lead in international regulatory cooperation for the global development of complex medicines. Similarly, the EU’s ability to align with partners such as the US Food and Drug Administration (FDA) on Good Manufacturing Practice (GMP) mutual recognition offers the possibility to strengthen the oversight of global manufacturing supply chains. Digital tools like electronic patient information leaflets (‘e-leaflet’) need to be leveraged to improve the flow of information to patients and eliminate the vast complexity of updating paper leaflets in over 20 languages across the EU.
Marc Alexander Mahl, Medicines for Europe President commented: “The dialogue between industry and regulators to optimise the regulation of pharmaceuticals is an essential part of access to medicines. We need to take material steps forward to grasp the opportunities in areas like e-leaflets and global development while carefully managing disrupters such as Brexit. ”
National authorities, regulators, industry leaders, and stakeholders gathered in London to discuss the role of pharmacovigilance in ensuring patient safety and access to safe medicines at the 12th Medicines for Europe Pharmacovigilance Conference.
As we move into an increasingly patient-centred future, simplification and improved communication should be at the heart of our pharmacovigilance strategy.
Digital technologies offer the promise of more pharmacovigilance data from different sources provided we can improve the capacity of the EMA pharmacovigilance system to better filter essential and non-essential information sent to companies for review. The EMA-industry dialogue should step up its efforts to streamline the functioning of the system.
Our industry also applauds the introduction of patient hearings which provide patients with a platform to share their views and contribute to better pharmacovigilance. This patient voice combined with targeted data will improve communication between industry, regulators, healthcare providers and patients in the future.
Adrian van den Hoven, Medicines for Europe Director General commented: “Efficient pharmacovigilance is paramount for the safe use of medicines. Industry and regulators have a shared responsibility to ensure that this system remains effective and efficient. We commend the regulatory community on the close cooperation to achieve results for patients who rely on medicines. We need to accelerate the use of structured data to streamline and focus pharmacovigilance systems on patient needs. Patient and healthcare practitioners are welcome contributors to this process.”
Medicines for Europe welcomes the publication of the European Commission Report on Competition Enforcement in the Pharmaceutical Sector (2009-2017).
This compilation of pharmaceutical competition law cases is part of the Health Council Conclusions of June 2016 on strengthening the balance in the pharmaceutical systems in the EU. These conclusions aim to ensure the timely availability of generic and biosimilar medicines for patient access and sustainable pharmaceutical budgets.
The report provides valuable information on how to prevent unnecessary and unlawful delays to generic and biosimilar medicines competition. Competition law scrutiny is essential to prevent misuse of the regulatory system to delay competition including the spread of misleading information to denigrate generic and biosimilar medicines in the market.
Adrian van den Hoven, Director General of Medicines for Europe, commented: “Today’s report shows the important role that competition rules play in the pharmaceutical sector. Building on the excellent work of the EC Sector Inquiry of 2009 and the results of this Report, Medicines for Europe is ready to support the European Commission and national competent authorities in removing barriers to proper competition (such as patent linkages or disparagement practices) and focus on policies and incentives to stimulate more competition in the off-patent sector. This is going to result in better access for patients and sustainable healthcare systems throughout Europe.”
Medicines for Europe welcomes today’s vote of the Legal Committee of the European Parliament (JURI), which combines the opinions of the Health (ENVI) and Trade (INTA) committees in support of a comprehensive SPC manufacturing waiver.
The compromise agreement by the JURI Committee includes the possibility to produce generic and biosimilar medicines during the SPC period for export purposes and to stockpile for two years to prepare for launch in the EU on day-1 after SPC expiry. This will stop the forced delocalization of pharmaceutical manufacturing outside of Europe and is a positive step forward to allow all manufacturers including SMEs to benefit from the manufacturing waiver. More importantly, patients and member states’ healthcare budgets will benefit from immediate access to generic and biosimilar medicines manufactured in Europe as soon as SPCs expire. The Parliament’s position is fully justified by the European Commission Impact assessment which underlines “an SPC manufacturing waiver for export and stockpiling would be the most effective and simplest option”.
The JURI committee also voted to implement the SPC manufacturing waiver starting in January 2021. While there is further room for improvement, this represents another step in the right direction to ensure that the SPC manufacturing waiver delivers on its promise of industrial jobs and lower costs for patients and healthcare systems.
The JURI committee also recognises the importance of protecting the right of manufacturers to keep commercially sensitive information confidential in the context of the notification procedure. We hope this common sense approach will be reflected in the final text of the SPC manufacturing waiver. However, we do not understand the logic of including falsified medicines requirements – which are for patient safety – into an EU regulation on pharmaceutical incentives.
Medicines for Europe Director General, Adrian van den Hoven, commented: “The Parliament has made a thorough review and introduced many positive changes to the SPC manufacturing waiver proposal. With some further fine-tuning of this text in the trialogue phase, the SPC manufacturing waiver will deliver on its promise for patient access, for pharmaceutical manufacturing jobs, and for sustainable healthcare budgets in Europe.”
The Medicines for Europe Board unanimously applauds last night’s vote in the European Parliament where, once again, parliamentarians voted for a comprehensive Supplementary Protection Certificate (SPC) manufacturing waiver. This has the potential of unlocking huge industrial job opportunities and healthcare savings as SPCs expire on blockbuster medicines over the next few years.
The International Trade Committee (INTA) introduced several important amendments to improve the original proposal while maintaining the exclusivity rights of the originator industry under the SPC.
The Trade Committee confirmed the opinion of the Health Committee by introducing the possibility of ‘Day 1’ launch to allow manufacturing for European patients and by removing requirements to disclose confidential business information under the notification procedure. The Trade Committee also introduced a proposal to improve the uniform application of the legislation across Europe with an improved applicability period.
The SPC manufacturing waiver will correct the implementation of the Supplementary Protection Certificate system which forces European manufacturers to delocalise manufacturing outside of Europe if they want to supply countries where the SPC does not apply, or to allow for ‘Day 1’ launches after SPC expiry in the EU. This has led to the loss of manufacturing capability in Europe while our non-European competitors such as Canada, India, China or the United States flourish.
Commenting, Adrian van den Hoven, Director General of Medicines for Europe, said “we thank the Trade Committee for not caving in to vested interests and foreign pressure by voting for a comprehensive SPC manufacturing waiver. This is not a technical measure. The manufacturing waiver is the first step in a policy to ensure Europe’s security of supply of medicines, to stop the delocalisation of production and to stimulate competition after SPC expiry. We now call on the Parliament’s Legal Committee to adopt a final report that will strengthen Europe’s ecosystem for pharmaceutical manufacturing.”
Yesterday, 29th November, members of the Competitiveness Council expressed strong support for an SPC manufacturing waiver. While we regret that a couple of countries are clearly supporting vested interests in their complete opposition to the waiver, at least it is now clear that they simply working to block the constructive efforts of the rest of the Council to reposition Europe as a global hub for the production of medicines. This constructive dialogue in the Council will pave the way for future trialogue negotiations with the European Parliament where we see similar efforts toward a comprehensive manufacturing waiver.
In this technical discussion, it is important to remember the objectives of the SPC manufacturing waiver for Europe:
Medicines for Europe reiterates its request to make the SPC manufacturing waiver a success for Europe by:
Medicine’s for Europe Director General Adrian van den Hoven said “The Council and Parliament can choose to support the manufacturing of generic and biosimilar medicines in Europe over delocalisation. We trust that the European interest will prevail.”
The introduction of comprehensive SPC manufacturing waiver key to unlocking huge industrial opportunities and healthcare savings, with €90 billion of blockbuster medicines coming off patent in 2020.
The Parliament’s Health Committee (ENVI) sent a clear signal of support with the adoption of a “day one” launch possibility to supply European patients with European manufactured medicines.
The SPC manufacturing waiver aims to correct the current implementation of Supplementary Protection Certificate system which blocks manufacturers from producing generic or biosimilar medicines for export to non-EU countries where the SPC does not apply, or from producing and stockpiling these medicines to allow for ‘Day One’ launches after SPC expiry in the EU. Because of the current restrictions, the EU pharma industry is forced to delocalise production to non-EU countries, like Canada, India, China or the United States.
The Health Committee also recognised the need to protect commercially confidential information in the context of a notification procedure.
Regrettably, the Health Committee maintained the very long lead time for implementing the waiver which will delay its ability to create manufacturing and access opportunities for many years.
Commenting, Adrian van den Hoven, Director General of Medicines for Europe, said “We welcome the Health Committee’s efforts to improve the SPC manufacturing waiver in relation to day one launch and the protection of confidential business information. We hope that this progress, together with a more reasonable date of application, will be agreed by the Parliament and the Council in a future final agreement. We urge the Parliament’s Legal Committee to adopt a final Opinion that includes these important priorities for health, for jobs and for a robust pharmaceutical eco-system.”
The European Commission and OECD – Health at a Glance: Europe 2018 –recommends further use of generic and biosimilar medicines to further tackle wasteful spending in healthcare systems. The uptake of generic and biosimilar medicines varies widely across countries despite the opportunities to treat more patients and improve the sustainability of healthcare budgets. There is a need for more demand-side policies and incentives to encourage the use of generic and biosimilar medicines.
Another recent publication from the European Commission “Inequalities in access to healthcare – A study of national policies 2018” highlights that most healthcare systems need to improve equality of access to healthcare. Since 2014, spending on new originator pharmaceuticals has risen due to a wave of new medicines in areas such as hepatitis C and oncology[i],[ii].
While these treatments bring hope to patients, pharmaceutical budgets struggle to pay for high-priced innovations. This has led to short-term cost-containment measures in pharmaceuticals which are undermining the sustainability and supply of essential off-patent medicines. This has led to withdrawals of medicines and a reduction of competition in several countries[iii].
Adrian van den Hoven, Medicines for Europe Director General mentions: “Improving better and more equitable access to medicines should be prioritized in Europe. This requires pro-generic and pro-biosimilar medicines policies based on healthy competition. Cutting spending on essential medicines to pay for high priced new medicines is a recipe for poorer access to medicines for Europeans.”
[i] Hello, $200B: Super-pricey new cancer drugs drive mega increases in treatment spending – https://www.fiercepharma.com/pharma/as-cancer-treatment-becomes-more-targeted-global-costs-are-heading-to-200b-report
[ii] IQVIA – Global Oncology Trends 2018 Innovation, Expansion and Disruption; https://www.iqvia.com/institute/reports/global-oncology-trends-2018
[iii] Medicines for Europe Reading List on Medicines’ shortages – https://www.medicinesforeurope.com/docs/20170927%20-%20Medicine%20shortages%20-%20Reading%20list_final.pdf
The 2nd Value Added Medicines conference gathered a wide range of experts in the healthcare community to raise awareness, inform and debate with the mutual intention to present solutions for maximising the benefits of and encouraging the development of continuous innovation. Adjustments in the healthcare processes – eg. adjustments on purchasing/procurement processes, acceptance of adequate evidence and, where needed, adjustment of pricing and reimbursement barriers – , as well as seizing the benefits of digital technologies and increased stakeholder collaboration should be maximised to bring value added medicines to patients.
Marc-Alexander Mahl, Medicines for Europe President, highlighted that “Today’s event brought stakeholders who care about patient access to medicines together to reflect on the role of continuous innovation to deliver efficient and sustainable solutions to patient needs. Value added medicines deliver patient-centred gains from both the clinical and economic perspective. To capture this innovation, we have to integrate value added medicines in healthcare systems and seize opportunities in digital healthcare. Stakeholder collaboration will be key to fully ensure these benefits reach patients and the healthcare community and society”.
The Value Added Medicines Sector Group also awarded two prizes for outstanding programmes which improve patient quality of life and/or adherence and/or demonstrate relevant value added benefits on existing treatments. Congratulations to our winners 2018:
Category 1 – ‘Be Educated and Empowered Patient (BEEP) Program’ – Education program for organ transplanted patients organised by The Hungarian Transplant Federation
Category 2 – ‘Keramod® Gel’ – an innovative 5% Imiquimod film-forming formulation to enhance patient´s compliance by reducing side effects developed by Laboratorios Ojer Pharma
More information about the prize winners will be available in the coming weeks. Please visit https://www.medicinesforeurope.com/value-added-medicines/ for more information.
Medicines for Europe is glad to announce the occasion of the first European Open Industry Day in Romania, which took place in Bucharest on October 31st. The objective of the day was to open up our industry’s doors to interested institutional stakeholders.
This initiative has been designed together with APMGR, the Romanian generic association, and Zentiva, who hosted the initiative, to showcase the strength of Europe’s local and regional pharmaceutical excellence.
“Our goal is to provide insight into the workings of pharmaceutical plants, showing the high-level standards of safety and quality of the generic, biosimilar and value-added medicines manufacturing chain and above all showing the end result of these processes – life enhancing, lifesaving medicines and products” said Sergio Napolitano, Director for Legal and External Affairs.
For the stakeholders present, debate and discussion focused on the key challenges we currently face in terms of market and industrial sustainability and seek to explore the opportunities for further growth in the sector. This was particularly pertinent in view of the upcoming Romanian Presidency of the Council of the European Union.
It is essential that Europe will maintain its primary role as a pharmaceutical hub for European patients by guaranteeing universal and timely access medicines. To ensure this, European generic and biosimilar medicines play a key role. IMS has calculated that between 2005 and 2015, across seven disease areas, twice as many patients have been treated without any impact on treatment costs.
Europe cannot rely anymore on third party manufacturers, it is of great importance to introduce a comprehensive SPC manufacturing waiver which supports greater patient access to medicines. This waiver would permit pharmaceutical companies to begin manufacturing medicines for export to non-EU countries during the SPC period as well as allowing these companies to be ready to supply in Europe on day 1 after patent expiry.
A comprehensive SPC manufacturing waiver would reduce these barriers and encourage a level playing field, both within the EU and on a global scale. Furthermore, the waiver will provide vast benefits to patients and EU healthcare services, including faster access to a more diversified medicines supply, a more cost-efficient medicines budget due to increased competition, and a guarantee of EU-quality generic and biosimilar medicines.
The continued development of local pharmaceutical manufacturing is essential to deliver results at the pan-European level – maintaining the EU’s position as a leader on the global stage.
For more information on the SPC manufacturing waiver, please visit http://www.spcwaiver.com/en/